NewAmsterdam Pharma(NAMS)

招股说明书

NewAmsterdam Pharma(NAMS)02-14 06:35

$NewAmsterdam Pharma(NAMS)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001193125-24-033967  Act: 33  Size: 1 MB 网页链接

当期报告

NewAmsterdam Pharma(NAMS)02-16 05:25

$NewAmsterdam Pharma(NAMS)$ 8-K Current report, items 1.01, 7.01, and 9.01 Accession Number: 0001193125-24-037559  Act: 34  Size: 732 KB 网页链接

招股信息更正说明

NewAmsterdam Pharma(NAMS)02-29 06:25

$NewAmsterdam Pharma(NAMS)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001193125-24-050794  Act: 33  Size: 792 KB 网页链接

超过5%股东持股披露「修订」

NewAmsterdam Pharma(NAMS)02-22 00:15

$NewAmsterdam Pharma(NAMS)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001193125-24-040964  Act: 34  Size: 328 KB 网页链接

招股信息更正说明

NewAmsterdam Pharma(NAMS)04-13 04:25

$NewAmsterdam Pharma(NAMS)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001193125-24-094677  Act: 33  Size: 784 KB 网页链接

持股变动声明

NewAmsterdam Pharma(NAMS)02-22 06:05

$NewAmsterdam Pharma(NAMS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-018045  Size: 4 KB 网页链接

年度财报

NewAmsterdam Pharma(NAMS)02-28 21:05

$NewAmsterdam Pharma(NAMS)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0000950170-24-021668  Act: 34  Size: 16 MB 网页链接

超过5%股东持股披露「修订」

NewAmsterdam Pharma(NAMS)03-02 05:35

$NewAmsterdam Pharma(NAMS)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001193125-24-056055  Act: 34  Size: 116 KB 网页链接

招股说明书

NewAmsterdam Pharma(NAMS)02-16 05:25

$NewAmsterdam Pharma(NAMS)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001193125-24-037547  Act: 33  Size: 1 MB 网页链接

持股变动声明

NewAmsterdam Pharma(NAMS)03-29 04:45

$NewAmsterdam Pharma(NAMS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-009330  Size: 6 KB 网页链接

讨论

产业链观察2023-06-05 22:18

#药闻简讯# $NewAmsterdam Pharma(NAMS)$ 宣布评估Obicetrapib的2b期剂量发现试验取得积极的顶线结果。
在接受10mg obicetrapib治疗的患者中，LDL-C中位数下降45.8%，达到了统计学意义上的主要终点（p < 0.0001）查看全文

讨论

chuminhua2023-01-19 11:01

1月17日，NewAmsterdam Pharma 宣布，其口服 CETP 抑制剂候选药物 obicetrapib 达到了 ROSE2 中期试验的主要终点，联合依折麦布用于高强度他汀类药物治疗的辅助治疗时，可显著降低低密度脂蛋白胆固醇。 据该公司称，这些数据支持将这款安进废弃的固定剂量组合推进到生物等效性和 III 期试验。https...查看全文

讨论

IPO收割机2022-11-23 23:06

$NewAmsterdam Pharma(NAMS)$ 开盘八十个点。沙发查看全文

招股说明书

$NewAmsterdam Pharma(NAMS)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001193125-24-102926  Act: 33  Size: 243 KB 网页链接

生效批准

$NewAmsterdam Pharma(NAMS)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-001001  Act: 33  Size: 1 KB 网页链接

招股信息更正说明

$NewAmsterdam Pharma(NAMS)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001193125-24-094677  Act: 33  Size: 784 KB 网页链接

持股变动声明

$NewAmsterdam Pharma(NAMS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040235  Size: 5 KB 网页链接

当期报告

$NewAmsterdam Pharma(NAMS)$ 8-K Current report, items 5.02, 7.01, and 9.01 Accession Number: 0001193125-24-082723  Act: 34  Size: 209 KB 网页链接

持股变动声明

$NewAmsterdam Pharma(NAMS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-009330  Size: 6 KB 网页链接

持股变动声明

$NewAmsterdam Pharma(NAMS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-037241  Size: 12 KB 网页链接

证券出售报告

$NewAmsterdam Pharma(NAMS)$ 144 Report of proposed sale of securities Accession Number: 0001974158-24-000017  Act: 33  Size: 5 KB 网页链接

招股说明书

$NewAmsterdam Pharma(NAMS)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001193125-24-065893  Act: 33  Size: 563 KB 网页链接

生效批准

$NewAmsterdam Pharma(NAMS)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-000622  Act: 33  Size: 1 KB 网页链接